Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
“Our first quarter financial results continue to demonstrate the successful transformation for Innoviva.
- “Our first quarter financial results continue to demonstrate the successful transformation for Innoviva.
- We are pleased with our first quarter performance, led by the strong launch of our novel therapeutic XACDURO®.
- Share repurchases: During the first quarter 2024, Innoviva repurchased 0.6 million shares of its outstanding common stock for $9.7 million.
- In the first quarter 2024, Innoviva invested an additional $35.0 million in one of our assets, Armata, to help advance its lead therapeutic phage candidates.